Kennedy Capital Management’s Blueprint Medicines BPMC Stock Holding History

Kennedy Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,836	Closed	-$620K	–	567
2025 Q2	$620K	Buy	4,836 +213	+5%	+$22.1K	0.01%	536
2025 Q1	$409K	Buy	4,623 +59	+1%	+$5.76K	0.01%	595
2024 Q4	$398K	Buy	4,564 +748	+20%	+$68.5K	0.01%	642
2024 Q3	$353K	Buy	3,816 +547	+17%	+$54.3K	0.01%	646
2024 Q2	$352K	Buy	3,269 +949	+41%	+$95K	0.01%	652
2024 Q1	$220K	Buy	+2,320	New	+$199K	﹤0.01%	699

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Kennedy Capital Management's BPMC Position: Q3 2025 in Review

Kennedy Capital Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4,836 shares — an estimated $620K sold.

Kennedy Capital Management first reported a position in BPMC in Q1 2024 and held it in 6 quarters. The position peaked at $620K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Kennedy Capital Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Kennedy Capital Management sold 4,836 Blueprint Medicines shares in Q3 2025, an estimated $620K.
Kennedy Capital Management first reported a position in Blueprint Medicines in Q1 2024 and held it in 6 quarters.
Kennedy Capital Management's Blueprint Medicines position peaked at $620K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Kennedy Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.